Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research note released on Saturday.

ALNY has been the topic of a number of other research reports. HC Wainwright restated a buy rating and issued a $395.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, March 5th. Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. They set a peer perform rating on the stock. The Goldman Sachs Group cut shares of Alnylam Pharmaceuticals from a buy rating to a neutral rating and cut their price target for the company from $230.00 to $173.00 in a report on Friday, February 16th. JPMorgan Chase & Co. increased their price target on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a neutral rating in a report on Thursday, February 1st. Finally, BMO Capital Markets restated an outperform rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Eight equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of Moderate Buy and an average target price of $216.12.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $147.70 on Friday. Alnylam Pharmaceuticals has a 1 year low of $143.52 and a 1 year high of $218.88. The company has a market cap of $18.60 billion, a P/E ratio of -41.49 and a beta of 0.39. The firm has a 50-day moving average of $153.53 and a 200 day moving average of $167.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.68) EPS. On average, equities research analysts expect that Alnylam Pharmaceuticals will post -4.54 earnings per share for the current fiscal year.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Services Advisors Inc. grew its stake in shares of Alnylam Pharmaceuticals by 9.4% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 11,850 shares of the biopharmaceutical company’s stock worth $1,935,000 after buying an additional 1,017 shares in the last quarter. MetLife Investment Management LLC bought a new stake in Alnylam Pharmaceuticals during the 1st quarter valued at about $1,268,000. Panagora Asset Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 96.4% in the 1st quarter. Panagora Asset Management Inc. now owns 6,565 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,223 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Alnylam Pharmaceuticals by 21.2% during the 1st quarter. Great West Life Assurance Co. Can now owns 62,369 shares of the biopharmaceutical company’s stock worth $10,786,000 after acquiring an additional 10,892 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Alnylam Pharmaceuticals by 1.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 181,271 shares of the biopharmaceutical company’s stock worth $29,601,000 after acquiring an additional 2,111 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.